Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash from Financing Activities (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Cash from Financing Activities for 8 consecutive years, with -$30000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities rose 99.91% year-over-year to -$30000.0, compared with a TTM value of $87000.0 through Sep 2025, down 99.98%, and an annual FY2024 reading of $519.8 million, up 107.88% over the prior year.
  • Cash from Financing Activities was -$30000.0 for Q3 2025 at Bicycle Therapeutics, up from -$45000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $549.6 million in Q2 2024 and bottomed at -$31.9 million in Q3 2024.
  • Average Cash from Financing Activities over 5 years is $57.7 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Cash from Financing Activities soared 3702850.0% in 2021, then tumbled 113.61% in 2024.
  • Year by year, Cash from Financing Activities stood at $190.7 million in 2021, then crashed by 96.91% to $5.9 million in 2022, then plummeted by 93.44% to $386000.0 in 2023, then tumbled by 47.41% to $203000.0 in 2024, then plummeted by 114.78% to -$30000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for BCYC at -$30000.0 in Q3 2025, -$45000.0 in Q2 2025, and -$41000.0 in Q1 2025.